About us
Avidicure has developed an entirely new antibody AVC booster targeted and potent immune-modulating therapy for patients, with broad applicability in oncology and auto-immune disease.
Our “AVC-Boosters” can safely deliver improved efficacy for a range of complex heterogenous diseases. They combine the best qualities of first-generation antibodies, engagers, checkpoint inhibitors and ADCs. Our AVC Boosters drive strong and orchestrated immunological responses, harnessing the full power of both the innate and adaptive immune system.
The Company completed a 37 million Euro seed round from a top-tier investor syndicate led by EQT-Life Sciences, with participation from Kurma Partners, BioGeneration Ventures, BOM and Curie capital.
First-in-class rationally designed multifunctional antibodies
AVC-Booster Platform
The fully owned proprietary AVC-Booster platform builds on a clinically proven antibody scaffold to which proprietary co-stimulatory domains are genetically fused. AVC-Boosters are avidity-engineered to only stimulate immune responses upon contact with tumor cells or other aberrant cells. This unique specificity drives conditional activation, reduces toxicity risks and enhances the therapeutic window.
The AVC-Booster platform was designed combining decades of antibody engineering know-how, in silico design capabilities and immunology expertise. The platform offers seamless plug-and-play functionality for an entire generation of new products, by allowing for rapid and efficient swapping of binding domains targeting different antigens of interest. AVC-Boosters are designed for scalable and cost-effective manufacturing based on well-established antibody production platforms.
Unique mode of action
Explanation here
Broad therapeutic potential
Pipeline
AVC-Boosters have broad potential across multiple therapeutic areas, including solid tumors, hematologic cancers and auto-immune diseases. Avidicure’s lead product is AVC-S-101, a TROP2-targeting booster that is being developed for non-small cell lung cancer and multiple other indications.
Leadership
Avidicure’s management team is uniquely qualified to develop this revolutionary new treatment modality, merging proven drug development leadership, strategic vision and scientific rigor. The executive team brings decades of biotechnology and pharmaceutical executive leadership experience, with demonstrated execution from early target discovery through development, manufacturing and commercialization, while playing key roles in the acquisitions of Crucell, Ablynx and Kiadis.
Board / SAB
Avidicure has a seasoned board, with deep track record in venture capital, life sciences and biotech
Join Us
Explore our exciting job opportunities and take your career to the next level.
Biomedical Engineer
Assist our customers and ensure they have the best experience with our services.
Read moreInterested in our research?
This is some more information in a pragraph